Extensively Drug-Resistant Typhoid Fever in the United States
Author(s) -
Michael Hughes,
Meseret G. Birhane,
Layne Dorough,
Jared Reynolds,
Hayat Caidi,
Kaitlin A. Tagg,
Caroline M Snyder,
Alexander T. Yu,
Shana M Altman,
Michelle M. Boyle,
Deepam Thomas,
Amy E Robbins,
HaeNa A Waechter,
Irina Cody,
Eric D. Mintz,
Bruce Gutelius,
Gayle Langley,
Louise Francois Watkins
Publication year - 2021
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofab572
Subject(s) - typhoid fever , medicine , azithromycin , enteric fever , empiric therapy , drug , intensive care medicine , pediatrics , virology , antibiotics , alternative medicine , microbiology and biotechnology , pharmacology , pathology , biology
Cases of extensively drug-resistant (XDR) typhoid fever have been reported in the United States among patients who did not travel internationally. Clinicians should consider if and where the patient traveled when selecting empiric treatment for typhoid fever. XDR typhoid fever should be treated with a carbapenem, azithromycin, or both.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom